Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rosiglitazone and the risk of adverse cardiovascular outcomes.

× No keyword cloud information.

6 in total

Review 1. Peroxisome proliferator-activated receptor gamma (PPAR-γ) and neurodegenerative disorders.

Authors: Yu-Chang Chen; Jui-Sheng Wu; Hsin-Da Tsai; Chien-Yu Huang; Jin-Jer Chen; Grace Y Sun; Teng-Nan Lin
Journal: Mol Neurobiol Date: 2012-03-21 Impact factor: 5.590

2. Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy.

Authors: S Wheeler; K Moore; C W Forsberg; K Riley; J S Floyd; N L Smith; E J Boyko
Journal: Diabetologia Date: 2013-06-25 Impact factor: 10.122

3. Activation of the endocannabinoid system mediates cardiac hypertrophy induced by rosiglitazone.

Authors: Ya-Han Liu; Yan Liu; Xu Zhang; Li Fang; Bei-Lei Zhao; Nan-Ping Wang
Journal: Acta Pharmacol Sin Date: 2022-02-21 Impact factor: 7.169

Review 4. Something old, something new and something very old: drugs for treating type 2 diabetes.

Authors: D Kaiser; E Oetjen
Journal: Br J Pharmacol Date: 2014-06 Impact factor: 8.739

Review 5. PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease.

Authors: Juan Carlos Corona; Michael R Duchen
Journal: Free Radic Biol Med Date: 2016-06-25 Impact factor: 7.376

Review 6. Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives.

Authors: Wuquan Deng; Sheng Qiu; Gangyi Yang; Bing Chen
Journal: Ther Clin Risk Manag Date: 2015-08-10 Impact factor: 2.423

6 in total